Drug Trial Radar · NCT07839000
A Clinical Trial to Evaluate [14C]-MK-4208/[14C]-TERN-701 in Healthy Adult Male Participants (MK-4208-002/TERN701-1016)
Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Feb 25, 2026
Primary completion
Apr 3, 2026
Study completion Apr 3, 2026
Sponsor
- Lead sponsor
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
- Sponsor type
- Industry
- First posted
- Sep 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of the study is to learn what happens to different forms of TERN-701 medications in a healthy person's body over time. Researchers will compare what happens to different forms of TERN-701 in a person's body over time. The goal of the study is to learn: * What happens to different forms of TERN-701 in a person's body over time. * The amount and number of different forms of TERN-701 that leave a person's body over time.
Conditions
- Healthy
Interventions
TERN-701Drug
Oral Liquid radiolabeled with \[14C\]-TERN-701
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Total Amount of [14C]-Radiolabel Excreted into Urine per Sampling Interval (Aeurine,14C,t1-t2)Time frame: Pre-dose and at designated time points up to 408 hours post dose
- Cumulative Percentage of Total Amount of [14C]-Radiolabel Excreted into Urine up to the Last Sampling Interval (Aeurine,14C)Time frame: Pre-dose and at designated time points up to 408 hours post dose
- Percentage of Total Amount of [14C]-Radiolabel Excreted into Feces per Sampling Interval (Aefeces,14C,t1-t2)Time frame: Pre-dose and at designated time points up to 408 hours post dose
- Cumulative Percentage of Total Amount of [14C]-Radiolabel Excreted into Feces Up to the Last Sampling Interval (Aefeces,14C)Time frame: Pre-dose and at designated time points up to 408 hours post dose
- Percentage of Total Amount of [14C]-Radiolabel Excreted from Body per Sampling Interval (Aetotal, 14C, t1-t2)Time frame: Pre-dose and at designated time points up to 408 hours post dose
- Cumulative Percentage of Total Excretion of [14C]-Radiolabel from the Body (Aetotal, 14C)Time frame: Pre-dose and at designated time points up to 408 hours post dose
- Maximum Concentration Observed in Plasma (Cmax) of TERN-701 in PlasmaTime frame: Pre-dose and at designated time points up to 408 hours post dose
- Time to Maximum Concentration Observed in Plasma (Tmax) of TERN-701 in PlasmaTime frame: Pre-dose and at designated time points up to 408 hours post dose
- Apparent Terminal Half-Life (t1/2) of TERN-701 in PlasmaTime frame: Pre-dose and at designated time points up to 408 hours post dose
- Area Under the Concentration-Time Curve from Time 0 to the Last Quantifiable Concentration (AUC0-last) of TERN-701 in PlasmaTime frame: Pre-dose and at designated time points up to 408 hours post dose
- Area Under the Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUC0-Inf) of TERN-701 in PlasmaTime frame: Pre-dose and at designated time points up to 408 hours post dose
- Apparent Oral Clearance (CL/F) of TERN-701 in PlasmaTime frame: Pre-dose and at designated time points up to 408 hours post dose
- Apparent Volume of Distribution (Vz/F) of TERN-701 in PlasmaTime frame: Pre-dose and at designated time points up to 408 hours post dose
- Total [14C]-Radiolabel in PlasmaTime frame: Pre-dose and at designated time points up to 408 hours post dose
- Tmax of Total [14C]-Radiolabel in PlasmaTime frame: Pre-dose and at designated time points up to 408 hours post dose
- t1/2 of Total [14C]-Radiolabel in PlasmaTime frame: Pre-dose and at designated time points up to 408 hours post dose
- AUC0-last of Total [14C]-Radiolabel in PlasmaTime frame: Pre-dose and at designated time points up to 408 hours post dose
- AUC0-Inf of Total [14C]-Radiolabel in PlasmaTime frame: Pre-dose and at designated time points up to 408 hours post dose
- Cmax of Total [14C]-Radiolabel in PlasmaTime frame: Pre-dose and at designated time points up to 408 hours post dose
- Tmax of Total [14C]-Radiolabel in Whole BloodTime frame: Pre-dose and at designated time points up to 408 hours post dose
- t1/2 of Total [14C]-Radiolabel in Whole BloodTime frame: Pre-dose and at designated time points up to 408 hours post dose
- AUC0-last of Total [14C]-Radiolabel in Whole BloodTime frame: Pre-dose and at designated time points up to 408 hours post dose
- AUC0-Inf of Total [14C]-Radiolabel in Whole BloodTime frame: Pre-dose and at designated time points up to 408 hours post dose
- Cmax of Total [14C]-Radiolabel in Whole BloodTime frame: Pre-dose and at designated time points up to 408 hours post dose
- Cumulative Amount of Total [14C]-Radiolabel Excreted in Urine (Aeurine)Time frame: Pre-dose and at designated time points up to 408 hours post dose
- Renal Clearence (CLr) of [14C] radioactivityTime frame: Pre-dose and at designated time points up to 408 hours post dose
- Percent of Dose Excreted as Radioactivity in Urine (%Feurine) of [14C] radioactivityTime frame: Pre-dose and at designated time points up to 408 hours post dose
- Cumulative Amount of Total [14C]-Radiolabel Excreted in Feces (Aefeces) of [14C] radioactivityTime frame: Pre-dose and at designated time points up to 408 hours post dose
- Percent of Dose Excreted as Radioactivity in Feces (%Fefeces) of [14C] radioactivityTime frame: Pre-dose and at designated time points up to 408 hours post dose
- Percentage Area Under the Concentration-Time Curve (AUC) of [14C]-Radiolabel TERN-701 Metabolite in PlasmaTime frame: Pre-dose and at designated time points up to 408 hours post dose
- Percentage of Administered Dose of [14C]-Radiolabel TERN-701 Metabolite in FecesTime frame: Pre-dose and at designated time points up to 408 hours post dose
- Percentage of the [14C]-Radiolabel TERN-701 Metabolite in UrineTime frame: Pre-dose and at designated time points up to 408 hours post dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pharmaron CPC Inc
Baltimore, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.